$NOVO B (+0,6%)
$NVO (+0,17%)
$LLY (+0,55%)
$CVS (-0,22%)
Eli Lilly $LLY (+0,55%) is ending its collaboration with CVS Health after CVS discontinued coverage of its weight-loss drug Zepbound in favor of Novo Nordisk's Wegovy $NOVO B (+0,6%) in favor of Novo Nordisk's Wegovy, Bloomberg reports. As of January 1, Lilly employees will transfer to Rightway, a new pharmacy benefits provider.
According to documents seen by Bloomberg, employees covered by Lilly's health plan will be automatically enrolled in drug coverage through pharmacy benefits provider Rightway starting Jan. 1.
The decision came after CVS decided to drop Lilly's weight-loss drug from its benefits package, while continuing to cover the competing product from Novo Nordisk.
